Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bardoxolone methyl Extended Access in CKD (EAGLE)
NCT03749447Phase 3Terminated
- Sponsor
- Biogen
- Start
- Mar 2019
- Primary completion
- Aug 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of bardoxolone methyl in chronic kidney disease (CKD), Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), sponsored by Biogen. Started Mar 2019; status: terminated.
02
Drugs
bardoxolone methyl
03
Conditions
chronic kidney disease (CKD)Alport syndromeautosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03749447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749447.